US Bancorp’s Nuvation Bio NUVB Stock Holding History

US Bancorp’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.78K	Buy	1,581 +106	+7%	+$591	﹤0.01%	3482
2025 Q4	$13.2K	Hold	1,475	–	–	﹤0.01%	3234
2025 Q3	$5.46K	Hold	1,475	–	–	﹤0.01%	3513
2025 Q2	$2.88K	Hold	1,475	–	–	﹤0.01%	3789
2025 Q1	$2.6K	Sell	1,475 -1,396	-49%	-$3.18K	﹤0.01%	3823
2024 Q4	$7.64K	Buy	2,871 +630	+28%	+$1.62K	﹤0.01%	3515
2024 Q3	$5.13K	Hold	2,241	–	–	﹤0.01%	3562
2024 Q2	$6.54K	Hold	2,241	–	–	﹤0.01%	3437
2024 Q1	$8.16K	Buy	+2,241	New	+$4.3K	﹤0.01%	3402
2023 Q1	–	Sell	-261	Closed	-$501	–	4174
2022 Q4	$501	Buy	+261	New	+$528	﹤0.01%	4001

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

US Bancorp's NUVB Position: Q1 2026 in Review

US Bancorp increased its Nuvation Bio (NUVB) stake by 7.2% in Q1 2026, buying an estimated $591 and bringing the position to 1,581 shares worth $6.78K. The position accounts for ﹤0.01% of the portfolio, ranked #3482.

US Bancorp first reported a position in NUVB in Q4 2022 and has held it in 10 quarters since. The position peaked at $13.2K in Q4 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

US Bancorp held 1,581 shares of Nuvation Bio worth $6.78K as of Q1 2026.
US Bancorp bought 106 Nuvation Bio shares in Q1 2026, an estimated $591.
Nuvation Bio made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3482 holding.
US Bancorp first reported a position in Nuvation Bio in Q4 2022 and has held it in 10 quarters since.
US Bancorp's Nuvation Bio position peaked at $13.2K in Q4 2025.
231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.